local_hospital

Policlinico Casilino

Address
lock Available on a paid plan

Policlinico Casilino - Advanced Cardiovascular Intervention Research

Policlinico Casilino is a specialized medical research center focused on innovative cardiovascular interventions and antithrombotic therapy optimization. The center demonstrates particular expertise in managing complex patients with multiple cardiovascular conditions requiring sophisticated treatment strategies.

  • Antithrombotic therapy optimization in atrial fibrillation patients undergoing percutaneous coronary intervention
  • Novel anticoagulation regimens following coronary stent implantation
  • Bleeding risk reduction strategies in patients requiring dual or triple antithrombotic therapy

The center's research program addresses critical clinical challenges in patients with atrial fibrillation who undergo percutaneous coronary intervention (PCI) with stent placement. Their investigations focus on balancing the delicate interplay between preventing thrombotic events such as stroke and myocardial infarction while minimizing bleeding complications through streamlined anticoagulation protocols involving P2Y12 inhibitors and direct oral anticoagulants (DOACs). This research is particularly significant for improving outcomes in high-risk cardiovascular patients requiring long-term anticoagulation management.

Site Overview

assignment
4
connected trials
corporate_fare
4
sponsors
science
11
IMPs

Activity Indicator

Last 6 months

0
Trials started
-100% vs previous period.
1
Trials started 6–12 months ago
4
Total trials linked
Moderately Active
trending_downDeclining-100%
Mar
Apr
May
Jun
Jul
Aug

Trial Flow

How this site's trials are distributed across therapeutic areas and active substances (IMPs), and how they're positioned within their overall lifecycle status. Flow thickness represents the number of unique trials.

Therapeutic areaarrow_forwardIMParrow_forwardLifecycle status
lock Available on a paid plan

Compounds & Molecules Timeline

The time span of clinical-trial activity for the main active substances (IMPs) studied at this site over the last 8 years. Each bar runs from the earliest trial start to the most recent end; a substance with a trial still open has no recorded end and is shown as ongoing.

Trial span Ongoing Showing last 8 years
lock Available on a paid plan

Sponsor & Partnership

Top sponsors by active trials, and the ones that have come back for more than one study.

Active trials
3
Sponsors (total)
4
Active sponsors
3

Sponsor Network

Top 3 by active trials.

lock +2 more on a paid plan

Partnership History

Sponsors with repeated collaboration (≥ 2 trials).

No repeated partnerships found.

Sponsor Network Graph

How sponsors and therapeutic areas connect across this site's active trials: each link is at least one active trial shared between them, and bigger nodes mean more activity. Click a node to see its exact connections.

Country Benchmark

Compared to 566 other sites in Italy

description
Trial volume
4
Outperforms 54% of sites
public
Therapeutic diversity
2areas
Outperforms 41% of sites
groups
Sponsor diversity
4sponsors
Outperforms 55% of sites

Therapeutic Area Benchmark — Italy

Select a therapeutic area to compare against other sites in Italy.

Competitor Comparison

Similar sites in the same country running a comparable number of trials (within ±30%), scored on how closely their trial portfolios match this one. Higher percentages mean a more similar profile.

Country: Italy

Market Share

Country: Italy

Therapeutic Area Market Share

Select a therapeutic area to view its disease coverage breakdown.

Heat Maps & Advanced Analytics

How often specific conditions appear in trials across this site and comparable sites from the same country. Each row is a site, each column a condition, and each cell the number of trials on it — darker means more activity.

Other Trials in Policlinico Casilino

lock Showing 1 of 4 trials — the rest is available on a paid plan.

Trial Sponsor Phase Status Start Date End Date
A Phase 2b/3, Adaptive, Randomized, Double-blind, Placebo-controlled, Multicenter Study to Assess the Efficacy and Safety of Danicamtiv in Participants with Symptomatic Genetic and Familial Dilated Cardiomyopathy (KINSHIP-DCM).Kardigan Inc.Phase IVRecruitingFeb 2026

IMP list

lock Showing 1 of 11 compounds — the rest is available on a paid plan.

IMP Trials Status First start Last start
Acetylsalicylic Acid1Unknown2024-12-162024-12-16

Upgrade this site to Business Plan

Own the profile, publish your feasibility data and reach sponsors directly.

Is something out of date?

Tell us what needs correcting and we'll update this profile.

lock Available to Business plan sites only.